Compare AbbVie Inc (ABBV) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Gold Fields Limited — how do they compare? AbbVie Inc trades at $249.53 (market cap $438.19B), while Gold Fields Limited trades at $40.84 (market cap $36.72B). The key difference: AbbVie Inc is far larger — about 11.9× Gold Fields Limited's market cap, and Gold Fields Limited pays the higher dividend (5.64%). Which is the better fit depends on your goals.
| ABBV | GFI | |
|---|---|---|
Market Cap | $438.19B | $36.72B |
Sector | Health | Basic Materials |
52-Week High | $263.58 | $61.52 |
52-Week Low | $197.38 | $29.31 |
Enterprise Value | $502.45B | $38.16B |
Dividend Yield | 2.79% | 5.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
Gold Fields (GFI) trades at $40.82, up 9.32% in 24 hours, reflecting strong momentum near recent highs. The stock shows a bullish technical signal with moving averages supporting upward trends, though RSI levels indicate potential overbought conditions. Fundamentally, GFI exhibits robust profitability with a 40.76% net income margin and attractive valuation metrics, including a P/E of 10.36. Recent earnings have been mixed, with a Q1 2025 beat but subsequent misses, while 2025 revenue is projected to surge to $8.8B. Institutional interest is evident with Allspring Global increasing its stake by 62.3% in Q1 2026 (SEC filing, 2026-07-18).
The outlook for GFI is positive, driven by strong gold prices and operational growth, with a consensus price target of $52.00 offering ~27% upside. Risks include cost inflation, geopolitical factors affecting mining operations, and volatile cash flows from heavy investing activities. Analyst sentiment is cautiously optimistic with 44% buy ratings, but investors should monitor execution on earnings targets and debt levels, which rose to 25.01% of assets in 2024.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
